Genelux Corporation (NASDAQ:GNLX) Position Trimmed by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. lowered its stake in shares of Genelux Corporation (NASDAQ:GNLX) by 42.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,745 shares of the company’s stock after selling 9,500 shares during the period. Stratos Wealth Partners LTD.’s holdings in Genelux were worth $34,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP lifted its stake in shares of Genelux by 51.4% in the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after purchasing an additional 52,958 shares during the last quarter. LPL Financial LLC boosted its holdings in Genelux by 72.3% during the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock valued at $222,000 after purchasing an additional 39,516 shares in the last quarter. 5T Wealth LLC bought a new stake in shares of Genelux in the 1st quarter worth about $49,000. Raymond James Financial Inc. bought a new stake in shares of Genelux during the fourth quarter worth $41,000. Finally, Miracle Mile Advisors LLC lifted its position in Genelux by 60.0% during the 1st quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the company’s stock worth $108,000 after buying an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Price Performance

Shares of GNLX opened at $3.40 on Friday. The firm’s 50 day simple moving average is $2.82 and its 200 day simple moving average is $3.16. Genelux Corporation has a 1-year low of $1.60 and a 1-year high of $5.89. The company has a market capitalization of $128.38 million, a P/E ratio of -3.86 and a beta of -0.34.

Genelux (NASDAQ:GNLX) last released its earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. On average, equities analysts anticipate that Genelux Corporation will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on GNLX shares. Benchmark lowered their target price on shares of Genelux from $25.00 to $23.00 and set a “speculative buy” rating for the company in a report on Thursday, May 8th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Genelux in a research note on Monday, March 31st. Finally, Wall Street Zen upgraded Genelux from a “sell” rating to a “hold” rating in a research note on Saturday, July 12th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.75.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.